Management of microscopic colitis: challenges and solutions
Julia Shor,1 Gustavo Churrango,1 Nooshin Hosseini,2 Christopher Marshall1 1Department of Gastroenterology, University of Massachusetts Medical School, Worcester, MA, USA; 2Department of Gastroenterology, Mount Sinai Hospital, New York, NY, USA Abstract: Microscopic colitis (MC) is a chronic inflamma...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-02-01
|
Series: | Clinical and Experimental Gastroenterology |
Subjects: | |
Online Access: | https://www.dovepress.com/management-of-microscopic-colitis-challenges-and-solutions-peer-reviewed-article-CEG |
id |
doaj-b621a1082a8842eaaefb261a670fc65d |
---|---|
record_format |
Article |
spelling |
doaj-b621a1082a8842eaaefb261a670fc65d2020-11-25T02:27:41ZengDove Medical PressClinical and Experimental Gastroenterology1178-70232019-02-01Volume 1211112044358Management of microscopic colitis: challenges and solutionsShor JChurrango GHosseini NMarshall CJulia Shor,1 Gustavo Churrango,1 Nooshin Hosseini,2 Christopher Marshall1 1Department of Gastroenterology, University of Massachusetts Medical School, Worcester, MA, USA; 2Department of Gastroenterology, Mount Sinai Hospital, New York, NY, USA Abstract: Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by nonbloody diarrhea in the setting of normal appearing colonic mucosa. MC has two main subtypes based on histopathologic features, collagenous colitis and lymphocytic colitis. Management of both subtypes is the same, with treatment goal of reducing the number of bowel movements and improving consistency. First-line treatment involves counseling the patient about decreasing their risk factors, like discontinuing smoking and avoiding medications with suspected association such as NSAIDs, proton pump inhibitor, ranitidine, and sertraline. Starting loperamide for immediate symptomatic relief is used as an adjunct to therapy with glucocorticoids. Budesonide is considered first-line treatment for MC given its favorable side effect profile and good efficacy, though relapse rates are high. Systemic glucocorticoids should be reserved to patients unable to take budesonide. In glucocorticoid refractory disease, medications that have been tried include cholestyramine, bismuth salicylate, antibiotics, probiotics, aminosalicylates, immunomodulators, and anti-tumor necrosis factor-alpha inhibitors. More research is needed for the creation of a systematic stepwise approach for relapsing and refractory disease. Keywords: microscopic colitis, diarrhea, collagenous colitis, lymphocytic colitis, management, inflammatory colitis https://www.dovepress.com/management-of-microscopic-colitis-challenges-and-solutions-peer-reviewed-article-CEGmicroscopic colitisdiarrheacollagenous colitislymphocytic colitismanagement |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shor J Churrango G Hosseini N Marshall C |
spellingShingle |
Shor J Churrango G Hosseini N Marshall C Management of microscopic colitis: challenges and solutions Clinical and Experimental Gastroenterology microscopic colitis diarrhea collagenous colitis lymphocytic colitis management |
author_facet |
Shor J Churrango G Hosseini N Marshall C |
author_sort |
Shor J |
title |
Management of microscopic colitis: challenges and solutions |
title_short |
Management of microscopic colitis: challenges and solutions |
title_full |
Management of microscopic colitis: challenges and solutions |
title_fullStr |
Management of microscopic colitis: challenges and solutions |
title_full_unstemmed |
Management of microscopic colitis: challenges and solutions |
title_sort |
management of microscopic colitis: challenges and solutions |
publisher |
Dove Medical Press |
series |
Clinical and Experimental Gastroenterology |
issn |
1178-7023 |
publishDate |
2019-02-01 |
description |
Julia Shor,1 Gustavo Churrango,1 Nooshin Hosseini,2 Christopher Marshall1 1Department of Gastroenterology, University of Massachusetts Medical School, Worcester, MA, USA; 2Department of Gastroenterology, Mount Sinai Hospital, New York, NY, USA Abstract: Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by nonbloody diarrhea in the setting of normal appearing colonic mucosa. MC has two main subtypes based on histopathologic features, collagenous colitis and lymphocytic colitis. Management of both subtypes is the same, with treatment goal of reducing the number of bowel movements and improving consistency. First-line treatment involves counseling the patient about decreasing their risk factors, like discontinuing smoking and avoiding medications with suspected association such as NSAIDs, proton pump inhibitor, ranitidine, and sertraline. Starting loperamide for immediate symptomatic relief is used as an adjunct to therapy with glucocorticoids. Budesonide is considered first-line treatment for MC given its favorable side effect profile and good efficacy, though relapse rates are high. Systemic glucocorticoids should be reserved to patients unable to take budesonide. In glucocorticoid refractory disease, medications that have been tried include cholestyramine, bismuth salicylate, antibiotics, probiotics, aminosalicylates, immunomodulators, and anti-tumor necrosis factor-alpha inhibitors. More research is needed for the creation of a systematic stepwise approach for relapsing and refractory disease. Keywords: microscopic colitis, diarrhea, collagenous colitis, lymphocytic colitis, management, inflammatory colitis
|
topic |
microscopic colitis diarrhea collagenous colitis lymphocytic colitis management |
url |
https://www.dovepress.com/management-of-microscopic-colitis-challenges-and-solutions-peer-reviewed-article-CEG |
work_keys_str_mv |
AT shorj managementofmicroscopiccolitischallengesandsolutions AT churrangog managementofmicroscopiccolitischallengesandsolutions AT hosseinin managementofmicroscopiccolitischallengesandsolutions AT marshallc managementofmicroscopiccolitischallengesandsolutions |
_version_ |
1724841335206182912 |